RxDoctor Payments Data

Russell Topham, MD

Internal Medicine · Tyler, TXNPI 1437138005

Payments from drug & device makers

$3,295in general payments, 2019–2025

Across 254 payments — averaging $12.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$467
  • Pfizer$338
  • Bayer$251
  • Johnson & Johnson$248
  • AbbVie$150
  • plus $726 from 17 others

What the payments were for

  • Food & beverage$3,22298%
  • Education$732%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,295 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$175,410
Medicare patients
399
Services billed
5,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$86,878
EliquisApixaban44$31,917
JardianceEmpagliflozin29$26,104
TrulicityDulaglutide19$24,704
MounjaroTirzepatide11$14,635
JanumetSitagliptin Phos/Metformin Hcl16$11,790
Repatha SureclickEvolocumab14$9,760
Tresiba Flextouch U-200Insulin Degludec14$8,133
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$5,516
Spiriva HandihalerTiotropium Bromide11$5,298
Levothyroxine Sodium398$4,717
Nebivolol Hcl79$4,619
Temazepam194$3,968
Omeprazole220$3,410
Memantine Hcl ErMemantine Hcl31$3,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,116$86,87892 claims
Lilly USA, LLCTrulicity, Mounjaro$467$39,33930 claims
PfizerEliquis$338$31,91744 claims
Boehringer IngelheimJardiance$33$26,10429 claims
MerckJanumet$28$11,79016 claims
GSKTrelegy Ellipta$17$5,51611 claims
AbbVieSynthroid$150$2,51354 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →